Sodium-glucose cotransporter-2 inhibitors (SGLT2i), which treat type 2 diabetes,19 reduce the major adverse cardiovascular events and all-cause mortality in individuals with or without diabetes.20,21 Studies also found that SGLT2i lower serum urate levels and reduce the risk of incident gout.22,23,24,25,26,27,28,29 However, to date, no study has specifically examined the association of SGLT2i with the risk of recurrent gout flares and all-cause mortality in patients with gout. This evidence concerns the gene SLC5A2 and gout.